Form 4: Exelixis CFO Senner Vests Significant Performance Shares

Exelixis' Executive Vice President and CFO, Christopher J. Senner, vested 149,474 performance-based restricted stock units after the company achieved certain performance criteria.

Summary

• Christopher J. Senner, EVP and CFO of Exelixis, Inc., reported changes in beneficial ownership.
• On January 15, 2026, 149,474 performance-based restricted stock units (PSUs) vested, representing 175% of the target shares (85,414) due to the achievement of performance criteria.
• 50% of these achieved shares (149,474 shares) were immediately issued.
• The remaining 50% of the achieved shares will vest on February 15, 2027, contingent on continuous service.
• 40,459 shares were withheld by Exelixis, Inc. to cover taxes related to the PSU vesting, at a price of $45.23 per share.
• Following these transactions, Senner directly beneficially owns 1,076,857 shares of common stock.
• Senner also indirectly owns 2,723 shares through the Exelixis, Inc. 401(k) Plan.
• His beneficial ownership includes 494,177 shares from RSUs and PSUs granted on March 31, 2025, which will be issued upon future vesting.

Sentiment

Score: 8

Explanation: The filing indicates strong positive performance by the company, as evidenced by the achievement of performance criteria leading to a 175% vesting of target PSUs for a key executive. This suggests successful operational execution and alignment of executive incentives with shareholder value. The only minor negative is the tax withholding, which is standard practice.

Positives

• Achievement of certain performance criteria by Exelixis, Inc., leading to the vesting of performance-based restricted stock units at 175% of target shares.
• Significant increase in the beneficial ownership of common stock by a key executive, Christopher J. Senner, indicating alignment with shareholder interests.
• The vesting of 149,474 shares demonstrates successful execution against pre-defined corporate goals.

Negatives

• 40,459 shares were withheld by the company to satisfy tax obligations, reducing the net shares received by the executive.

Risks

• The vesting of the remaining 50% of the achieved shares (on February 15, 2027) is subject to Christopher J. Senner's continuous service through that date.

Future Outlook

The remaining 50% of the achieved performance-based restricted stock units (149,474 shares) are scheduled to vest on February 15, 2027, provided Christopher J. Senner maintains continuous service. Additionally, 494,177 shares from other restricted stock units and performance-based restricted stock units granted on March 31, 2025, are expected to be issued upon their respective future vesting dates.

Management Comments

• The Compensation Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 175% of the Target Shares.

Industry Context

This Form 4 filing reflects a routine executive compensation event in the biotechnology sector, where performance-based equity awards are common tools to align executive incentives with company performance and shareholder value. The achievement of performance criteria leading to a higher vesting percentage (175% of target) suggests strong operational execution by Exelixis, which is a positive signal within the competitive biotech landscape.

Comparison to Industry Standards

• Performance-based restricted stock units (PSUs) with vesting tied to specific company achievements are a standard practice in executive compensation across the biotechnology and pharmaceutical industries, similar to programs at companies like Amgen, Gilead Sciences, or Biogen.
• The 175% achievement of target shares indicates strong performance against the set criteria, which is generally considered a positive outcome compared to typical vesting scenarios where target or below-target achievement might occur.
• The practice of withholding shares for tax purposes upon vesting is a common mechanism for managing tax liabilities for equity awards, consistent with practices observed at most publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact as the vesting of performance-based awards at 175% of target indicates strong company performance and management's alignment with shareholder interests.
• Employees: No direct impact on general employees, but it highlights the company's compensation structure for executives.
• Management: Positive impact for Christopher J. Senner due to significant equity vesting, reinforcing retention and motivation.

Next Steps

• The remaining 50% of the achieved PSU shares are expected to vest on February 15, 2027, subject to continuous service.
• Other RSUs and PSUs granted on March 31, 2025, will vest at future dates.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, Performance Shares, CFO, Executive Compensation, Biotechnology